Welcome to our dedicated page for Candel Therapeutics SEC filings (Ticker: CADL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Candel Therapeutics, Inc. (CADL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Candel is a clinical-stage biopharmaceutical company whose common stock trades on the Nasdaq Global Market under the symbol CADL, as noted in multiple Form 8-K filings. Its filings document material events related to its multimodal viral immunotherapy programs, capital structure, and key agreements.
Investors can review current reports on Form 8-K describing clinical and corporate milestones, such as interim data from the phase 1b trial of CAN-3110 in recurrent glioblastoma, progress with CAN-2409 in localized prostate cancer, NSCLC, and PDAC, and strategic decisions to prioritize certain indications. Other 8-K filings outline financing arrangements, including a Loan and Security Agreement with Trinity Capital Inc. for up to $130 million in term loans, registered direct equity offerings under an effective shelf registration statement, warrant amendments, and lease extensions for facilities in Needham, Massachusetts.
These filings also identify when Candel issues press releases on quarterly financial results, R&D events, and material agreements, and they confirm that CADL common stock is registered under Section 12(b) of the Exchange Act. By examining items such as Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, and Regulation FD Disclosure, users can understand how Candel reports on its financial position, capital resources, and clinical program updates.
On Stock Titan, AI-powered tools can help summarize lengthy Candel filings, highlight key sections, and surface references to topics like CAN-2409, CAN-3110, the enLIGHTEN™ Discovery Platform, and regulatory designations. This allows readers to quickly identify information on term loan covenants, equity offerings, and clinical data disclosures without manually parsing each document.
Candel Therapeutics director Paul B. Manning, through The Paul B. Manning Revocable Trust, completed an open-market purchase of 550,458 shares of common stock at
Candel Therapeutics entered into an underwriting agreement for a public stock offering of 18,348,624 common shares at
Candel estimates net proceeds of about
Candel Therapeutics is offering 18,348,624 shares of common stock in a primary offering at a public offering price of
The prospectus supplement discloses a related Purchase Agreement with funds managed by RTW Investments, LP under which the company would receive
Candel Therapeutics is offering $100,000,000 of its common stock. The preliminary prospectus supplement dated February
The cover states the offering is of shares of common stock listed on the Nasdaq Global Market under the symbol CADL. The prospectus supplement references preliminary cash of approximately
Candel Therapeutics entered a royalty-based funding agreement with funds managed by RTW Investments tied to its lead therapy aglatimagene besadenovec (CAN-2409) for intermediate- and high-risk localized prostate cancer. RTW will pay
In return, RTW will receive a tiered royalty on U.S. net sales: 4.67% on annual sales up to
Candel also reported preliminary, unaudited cash and cash equivalents of approximately
Candel Therapeutics Chief Technology Officer Seshu Tyagarajan received a new stock option grant. On January 26, 2026, he was granted options to purchase 154,000 shares of Candel Therapeutics common stock at an exercise price of $6.01 per share.
The options vest in forty-eight equal monthly installments starting after January 26, 2026, as long as he continues to serve the company on each vesting date. After this grant, he beneficially owns 154,000 stock options directly.
Candel Therapeutics Chief Medical Officer William Garrett Nichols received a stock option award reported on a Form 4. On January 26, 2026, he was granted an option to buy 136,500 shares of Candel common stock at an exercise price of $6.01 per share.
The option vests in 48 equal monthly installments following January 26, 2026, contingent on his continued service. The option expires on January 26, 2036. After this grant, Nichols directly beneficially owns 136,500 derivative securities linked to Candel common stock.
Candel Therapeutics, Inc. reported a new stock option grant to its Chief Financial Officer, Charles Schoch. On January 26, 2026, he received options to purchase 232,000 shares of common stock at an exercise price of $6.01 per share.
These options vest over time. The underlying shares will vest and become exercisable in forty-eight equal monthly installments following January 26, 2026, and each installment depends on his continued service with the company on the relevant vesting date.
Candel Therapeutics, Inc. reported that its Chief Executive Officer and director, Paul Peter Tak, received a grant of stock options. On January 26, 2026, he was awarded an option to purchase 629,000 shares of common stock at an exercise price of $6.01 per share.
The option was granted directly to him and is subject to time-based vesting. The underlying shares vest in 48 equal monthly installments starting after January 26, 2026, contingent on his continued service with the company on each vesting date. Following this grant, he beneficially owned stock options for 629,000 shares.
Candel Therapeutics Chief Scientific Officer granted stock options
Candel Therapeutics’ Chief Scientific Officer, Francesca Barone, received a stock option to buy 232,000 shares of common stock at an exercise price of $6.01 per share. The option was granted on January 26, 2026 and expires on January 26, 2036.
The option vests over time rather than all at once. The shares underlying the option vest and become exercisable in 48 equal monthly installments following January 26, 2026, as long as Barone continues serving the company on each vesting date. After this grant, she beneficially owns 232,000 stock options directly.